Safingol is under clinical development by CerRx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Safingol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Safingol overview

Safingol is under development for the treatment of adult non-Hodgkin's lymphoma and solid tumor. It is administered by intravenous route. The drug candidate acts by targeting protein kinase C. Safingol is a saturated derivative of sphingosine. It resembles the normal precursor molecule of dihydroceramides, called sphinganine.

CerRx overview

CerRx is a drug discovery company that discovers and develops anticancer drugs for cancer patients. The company provides products such as fenretinide, safingol and ppmp. Its fenretinide is synthesized from vitamin A, contains low level of bone marrow toxicity and increases ceramide waxes in cancer cells to prevent further growth and kills cancer cells. CerRx’s safingol is an artificial ceramide precursor that prevents cancer by killing fenretinide in cancer cells. The company develops therapeutics to stimulate overproduction of ceramides in cancer cells. It also conducts various research and development programs. CerRx is headquartered in Lubbock, Texas, the US.

For a complete picture of Safingol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.